Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk

被引:14
|
作者
Inzaule, Seth C. [1 ,2 ,3 ]
Weidle, Paul J. [4 ]
Yang, Chunfu [4 ]
Ndiege, Kenneth [1 ]
Hamers, Raph L. [2 ,3 ]
de Wit, Tobias F. Rinke [2 ,3 ]
Thomas, Timothy [4 ]
Zeh, Clement [5 ]
机构
[1] Kenya Govt Med Res Ctr, Kisumu, Kenya
[2] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[3] Amsterdam Inst Global Hlth & Dev Amsterdam, Amsterdam, Netherlands
[4] Ctr Dis Control & Prevent, Atlanta, GA USA
[5] Ctr Dis Control & Prevent, Kisumu, Kenya
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; TO-CHILD TRANSMISSION; REVERSE-TRANSCRIPTASE; ANTIRETROVIRAL THERAPY; HIV; SUBTYPE; INHIBITOR; PATTERNS; PREVENTION; IMPACT;
D O I
10.1093/jac/dkw039
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: K65R is a relatively rare drug resistance mutation (DRM) selected by the NRTIs tenofovir, didanosine, abacavir and stavudine and confers cross-resistance to all NRTIs except zidovudine. Selection by other NRTIs is uncommon. Objectives: In this study we investigated the frequency of emergence of the K65R mutation and factors associated with it in HIV-1-infected infants exposed to Low doses of maternal Lamivudine, zidovudine and either nevira pine or nelfinavir ingested through breast milk, using specimens collected from the Kisumu Breastfeeding Study. Methods: Plasma specimens with viral Load >= 1000 copies/mL collected from HIV-infected infants at 0-1, 2, 6, 14, 24 and 36 weeks of age and maternal samples at delivery were tested for HIV drug resistance using Sanger sequencing of the polymerase gene. Factors associated with K65R emergence were assessed using Fisher's exact test and the Wilcoxon rank-sum test. Results: K65R was detected in samples from 6 of the 24 infants (25%) who acquired HIV-1 infection by the age of 6 months. K65R emerged in half of the infants by 6 weeks and in the rest by 14 weeks of age. None of the mothers at delivery or the infants with a positive genotype at first time of positivity had the K65R mutation. Infants with K65R had Low baseline CD4 cell counts (P=0.014), were more Likely to have DRMs earlier (<= 6 weeks versus >= 14 weeks, P=0.007) and were more Likely to have multiclass drug resistance (P=0.035). M184V was the most common mutation associated with K65R emergence. K65R had reverted by 3 months after cessation of breastfeeding. Conclusions: A high rate of K65R emergence may suggest that ingesting Low doses of Lamivudine via breast milk could select for this mutation. The presence of this mutation may have a negative impact on future responses to NRTI-based ART. More in vitro studies are, however, needed to establish the molecular mechanism for this selection.
引用
收藏
页码:1619 / 1626
页数:8
相关论文
共 13 条
  • [1] Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing stavudine, lamivudine and nevirapine first-line antiretroviral therapy
    Hawkins, C.
    Chaplin, B.
    Idoko, J.
    Idehen, C.
    Adewole, I.
    Gashau, W.
    Murphy, R.
    Kanki, P.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S78 - S78
  • [2] Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing stavudine, lamivudine and nevirapine first-line antiretroviral therapy
    Hawkins, C.
    Chaplin, B.
    Idoko, J.
    Idehen, C.
    Adewole, I.
    Gashau, W.
    Murphy, R.
    Kanki, P.
    ANTIVIRAL THERAPY, 2007, 12 : S78 - S78
  • [3] The K65R mutation is rarely detected as a minority quasispecies in therapy-naive, chronically HIV-1-infected persons
    Metzner, K. J.
    Walter, H.
    Rauch, P.
    Braun, P.
    Knechten, H.
    Ehret, R.
    Mueller, M.
    Klauke, S.
    van Lunzen, J.
    Ranneberg, B.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S52 - S52
  • [4] The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations
    White, KL
    Chen, JM
    Feng, JY
    Morgot, NA
    Ly, JK
    Ray, AS
    MacArthur, HL
    McDermott, MJ
    Swaminathan, S
    Miller, MD
    ANTIVIRAL THERAPY, 2006, 11 (02) : 155 - 163
  • [5] Minority K65R Variants and Early Failure of Antiretroviral Therapy in HIV-1-infected Eritrean Immigrant
    Bansal, Vineeta
    Metzner, Karin J.
    Niederoest, Barbara
    Leemann, Christine
    Boeni, Juerg
    Guenthard, Huldrych F.
    Fehr, Jan S.
    EMERGING INFECTIOUS DISEASES, 2011, 17 (10) : 1966 - 1968
  • [6] Prevalence of the K65R Resistance Reverse Transcriptase Mutation in Different HIV-1 Subtypes in Israel
    Turner, Dan
    Shahar, Eduardo
    Katchman, Eugene
    Kedem, Eynat
    Matus, Natasha
    Katzir, Michal
    Hassoun, Gamal
    Pollack, Shimon
    Kessner, Rivka
    Wainberg, Mark A.
    Avidor, Boaz
    JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (09) : 1509 - 1512
  • [7] Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)
    Gibb, DM
    Walker, AS
    Kaye, S
    De Rossi, A
    Ait-Khaled, M
    Pillay, D
    Muñoz-Fernandez, MA
    Loveday, C
    Compagnucci, A
    Dunn, DT
    Babiker, AG
    ANTIVIRAL THERAPY, 2002, 7 (04) : 293 - 303
  • [8] Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine
    Sungkanuparph, Somnuek
    Manosuthi, Weerawat
    Kiertiburanakul, Sasisopin
    Saekang, Nipa
    Pairoj, Wantanit
    Chantratita, Wasun
    JOURNAL OF CLINICAL VIROLOGY, 2008, 41 (04) : 310 - 313
  • [9] Prevalence of the K65R mutation in subtype C HIV-1-infected subjects failing TDF-containing first-line antiretroviral therapy in South Africa using deep sequencing
    Casadella, M.
    Noguera-Julian, M.
    Sunpath, H.
    Gordon, M.
    Kuritzkes, D. R.
    Marconi, V.
    Paredes, R.
    ANTIVIRAL THERAPY, 2014, 19 : A76 - A76
  • [10] Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels
    Kozal, Michael J.
    Chiarella, Jennifer
    St John, Elizabeth P.
    Moreno, Elizabeth A.
    Simen, Birgitte B.
    Arnold, Todd E.
    Lataillade, Max
    ANTIVIRAL THERAPY, 2011, 16 (06) : 925 - 929